Janssen seeks EU approval of new indication for CAR-T therapy

CAR-T therapy

The Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a Type II variation application to the European Medicines Agency (EMA) seeking approval of Carvykti (ciltacabtagene autoleucel; cilta-cel) for relapsed and lenalidomide-refractory multiple myeloma.

The application is supported by data from the Phase III CARTITUDE-4 study, which evaluated the safety profile and efficacy of cilta-cel in the treatment of patients who received one to three prior lines of therapy.

CARTITUDE-4 was the first randomised Phase III study investigating the efficacy of a cell therapy as early as after first relapse in multiple myeloma.

“The previous European Commission approval recognised the potential for cilta-cel to positively impact outcomes for people living with relapsed and refractory multiple myeloma,” said Edmond Chan, Senior Director, EMEA Therapeutic Area Lead Haematology, Janssen-Cilag Limited.

“Today’s submission to the EMA is an important step towards helping patients benefit from this CAR-T therapy earlier in their treatment journey. If approved, this will be the first and only CAR-T therapy available to treat relapsed and refractory multiple myeloma patients as early as second line.”

The CARTITUDE-4 study results will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on Monday June 5, 2023.

Cilta-cel is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous T cell immunotherapy, which involves reprogramming a patient’s own T cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express BCMA. The CAR-modified T cells express fusion proteins of antigen receptors against tumour-associated surface antigens and T cell activation domains, and upon binding to BCMA-expressing cells redirect the effector T cells and enhance tumour-specific immunosurveillance.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free